Moleculin Biotech flagged for Nasdaq bid-price breach
Moleculin Biotech faces Nasdaq minimum bid price noncompliance without the usual cure period and will seek a hearing to avoid potential delisting while its stock continues trading.
Rhea-AI Filing Summary
Moleculin Biotech, Inc. (MBRX) reports that on September 15, 2026 it received a Nasdaq staff determination letter stating that the company is not in compliance with the $1.00 minimum bid price requirement, because its common stock’s closing bid price was below $1.00 for 30 consecutive business days from July 31, 2026 through September 11, 2026. Due to a prior 1-for-25 reverse stock split effected on December 1, 2025, Nasdaq Listing Rule 5810(c)(3)(A)(iv) makes the company ineligible for the usual 180‑day compliance period. Moleculin plans to request a hearing before the Nasdaq Hearings Panel; a timely request will stay any suspension or delisting, and the stock will continue trading on The Nasdaq Capital Market during the hearing process, though there is no assurance continued listing will be granted.
Positive
- None.
Negative
- Nasdaq has notified Moleculin Biotech that it is not in compliance with the $1.00 minimum bid price rule after 30 consecutive business days below that level, and the company is ineligible for the usual 180‑day compliance period due to a recent reverse stock split, increasing delisting risk.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Key Figures
Minimum bid price threshold: $1.00 per share
Consecutive days below minimum bid price: 30 business days
Reverse stock split ratio: 1-for-25
+1 more
4 metrics
Minimum bid price threshold
$1.00 per share
Nasdaq Capital Market continued listing requirement under Nasdaq Listing Rule 5550(a)(2)
Consecutive days below minimum bid price
30 business days
Closing bid below $1.00 from July 31, 2026 through September 11, 2026
Reverse stock split ratio
1-for-25
Reverse stock split of common stock effected on December 1, 2025
Date of Nasdaq staff determination letter
September 15, 2026
Notice of noncompliance with the Minimum Bid Price Requirement
Key Terms
Minimum Bid Price Requirement, Nasdaq Listing Rule 5550(a)(2), Nasdaq Listing Rule 5810(c)(3)(A)(iv), reverse stock split, +2 more
6 terms
Minimum Bid Price Requirement market
"compliance with the minimum bid price requirement for continued listing"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"set forth in Nasdaq Listing Rule 5550(a)(2)"
Nasdaq Listing Rule 5810(c)(3)(A)(iv) regulatory
"pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv)"
reverse stock split financial
"effected a 1-for-25 reverse stock split of the Common Stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Nasdaq Hearings Panel regulatory
"request for a hearing before the Nasdaq Hearings Panel"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
forward-looking statements regulatory
"contains “forward-looking statements” within the meaning of Section 27A"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What triggered the Nasdaq noncompliance notice for MBRX?
Nasdaq notified Moleculin Biotech that the closing bid price of its common stock was below $1.00 per share for 30 consecutive business days, from July 31, 2026 through September 11, 2026, violating the Minimum Bid Price Requirement for The Nasdaq Capital Market.
Why is Moleculin Biotech (MBRX) not getting the usual 180-day cure period?
The company is ineligible for the standard 180‑day compliance period under Nasdaq Listing Rule 5810(c)(3)(A) because it previously effected a 1-for-25 reverse stock split of its common stock on December 1, 2025, invoking Rule 5810(c)(3)(A)(iv).
What actions is Moleculin Biotech (MBRX) taking in response to the Nasdaq notice?
Moleculin Biotech intends to make a timely request for a hearing before the Nasdaq Hearings Panel in accordance with the Nasdaq Listing Rule 5800 Series, seeking continued listing despite not meeting the Minimum Bid Price Requirement.
What are the risks to Moleculin Biotech (MBRX) from this Nasdaq determination?
There is no assurance that the company’s request for continued listing will be granted or that it will regain and maintain compliance with the Minimum Bid Price Requirement and other Nasdaq continued listing standards, creating a risk of eventual delisting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): September 15, 2026
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction of Incorporation or Organization) | (Commission File No.) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices and zip code)
(713 ) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol (s) | Name of each exchange on which registered |
The |
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On September 15, 2026, Moleculin Biotech, Inc. (the “Company”) received a letter (the “Staff Determination Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), has been below $1.00 per share for the previous 30 consecutive business days (from July 31, 2026 through September 11, 2026) and, as a result, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).
Ordinarily, a company that fails to meet the Minimum Bid Price Requirement would be afforded a 180-calendar day compliance period pursuant to Nasdaq Listing Rule 5810(c)(3)(A) to regain compliance. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Staff has determined that the Company is not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A), because the Company has effected a reverse stock split in the prior one-year period. As previously disclosed, the Company effected a 1-for-25 reverse stock split of the Common Stock on December 1, 2025.
The Company intends to make a timely request for a hearing before the Nasdaq Hearings Panel (the “Panel”), in accordance with the procedures set forth in the Nasdaq Listing Rule 5800 Series. A timely request for a hearing will stay any suspension or delisting action pending the Panel’s decision, and the Company’s Common Stock will continue to trade on The Nasdaq Capital Market during the pendency of the hearing process. There can be no assurance that the Company’s request for continued listing will be granted or that the Company will be able to regain and maintain compliance with the Minimum Bid Price Requirement or all other applicable requirements for continued listing on The Nasdaq Capital Market.
Forward-Looking Statements
This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the Company’s intent to request a hearing before the Panel, the Company’s ability to regain and maintain compliance with the Minimum Bid Price Requirement and other applicable Nasdaq continued listing requirements, and the outcome of any Panel hearing. Forward-looking statements are subject to a number of risks and uncertainties, including that the Panel may deny the Company’s request for continued listing or condition continued listing on requirements that the Company may not be able to satisfy, that the Company may not regain compliance with the Minimum Bid Price Requirement, and other risks and uncertainties set forth from time to time in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOLECULIN BIOTECH, INC. |
|
Date: September 18, 2026 By: /s/ Jonathan P. Foster Jonathan P. Foster Chief Financial Officer |